Citius Oncology, Inc. Common Stock (CTOR) is a publicly traded Healthcare sector company. As of May 21, 2026, CTOR trades at $0.86 with a market cap of $77.07M and a P/E ratio of -2.37. CTOR moved +0.00% today. Year to date, CTOR is -28.17%; over the trailing twelve months it is -7.19%. Its 52-week range spans $0.49 to $6.19. Analyst consensus is buy with an average price target of $6.00. Rallies surfaces CTOR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Citius Oncology Secures $36.5M Financing, Posts $5.6M LYMPHIR Launch Revenue: Citius Oncology generated $5.6 million in LYMPHIR net revenue at 80% gross margins in its launch quarter, with 83% of target accounts on formulary and near 100% commercial lives covered without denials. It secured $36.5 million in financing to complete a full U.S. field force by mid-summer.
| Metric | Value |
|---|---|
| Price | $0.86 |
| Market Cap | $77.07M |
| P/E Ratio | -2.37 |
| EPS | $-0.34 |
| Dividend Yield | 0.00% |
| 52-Week High | $6.19 |
| 52-Week Low | $0.49 |
| Volume | 1.66K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-24.76M |
| Gross Margin | 0.00% |
1 analysts cover CTOR: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $6.00.